Activities
Early Interventions for Treating Influenza: Economic Evaluation in Managed Care Setting
0290-0000-19-105-H01-P
This program will examine the clinical evidence associated with approved agents for the treatment of influenza.
1.50
Examining von Willebrand Disease Treatment and the Role of Specialty Pharmacy Services
0290-0000-19-111-H01-P
This program will analyze the data of FDA-approved VWD factors and identify their role in therapy.
1.50
Examining Peanut Allergy Pathophysiology, Immunotherapy Data, and Health Care Utilization
0290-0000-19-110-H01-P
This program will apply knowledge of novel immunotherapies and desensitization to improve patient quality of care upon integration of peanut allergy immunotherapies into the treatment paradigm.
1.50
Clinical Updates and Cost Management Strategies in Treating Idiopathic Pulmonary Fibrosis
0290-0000-19-106-H01-P
This program explain the use of cost-effectiveness data to develop IPF management plans.
1.50